TherapeuticsMD financials
$2.04−2.39%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $869.0K | $724.0K | $893.0K | $784.0K | $952.0K | $393.0K | $667.0K | $547.0K | $234.0K | $313.0K | $502.0K | -$53.0K |
| Gross profit | $869.0K | $724.0K | $893.0K | $784.0K | $952.0K | $393.0K | $667.0K | $547.0K | $234.0K | $313.0K | $617.0K | -$73.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 122.9% | 137.7% |
| Operating income | -$816.0K | -$723.0K | -$1.6M | -$862.0K | -$695.0K | -$1.3M | -$652.0K | -$1.1M | -$2.8M | -$1.1M | -$1.5M | -$1.8M |
| Net income | $155.0K | $95.0K | -$619.0K | $152.0K | $551.0K | -$653.0K | $252.0K | -$609.0K | -$1.1M | -$734.0K | -$883.0K | -$3.4M |
| Net margin | 17.8% | 13.1% | −69.3% | 19.4% | 57.9% | −166.2% | 37.8% | −111.3% | −465.8% | −234.5% | −175.9% | 6373.6% |
| Diluted EPS | $0.01 | $0.01 | $-0.05 | $0.01 | $0.05 | $-0.06 | $0.02 | $-0.05 | $-0.09 | $-0.06 | $-0.08 | $-0.32 |
| EBITDA | -$721.0K | -$629.0K | -$1.6M | -$734.0K | -$599.0K | -$1.2M | -$1.8M | -$1.0M | -$1.3M | -$1.0M | -$859.0K | -$1.7M |
| Operating cash flow | $762.0K | $944.0K | $368.0K | $1.0M | $311.0K | $699.0K | $12.0K | -$185.0K | $894.0K | $11.0K | -$7.8M | -$2.5M |
| Free cash flow | $762.0K | $944.0K | $368.0K | $1.0M | $311.0K | $699.0K | $12.0K | -$185.0K | $894.0K | $11.0K | -$7.8M | -$2.5M |
| Diluted shares | 11.6M | 11.6M | 11.6M | 11.6M | 11.6M | 11.6M | 11.5M | 11.5M | 11.5M | 11.5M | 11.1M | 10.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $9.2M | $8.4M | $7.5M | $7.1M | $6.1M | $5.7M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $37.5M | $37.6M | $37.7M | $38.7M | $38.5M | $38.2M |
| Total liabilities | $10.4M | $10.6M | $10.8M | $11.2M | $11.2M | $11.5M |
| Shareholders' equity | $27.1M | $27.0M | $26.9M | $27.4M | $27.3M | $26.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology